Citation Information :
Bhat K, Goyal S, Meshram T, Sankanagoudar S. Prokineticin-2 and Procalcitonin's Diagnostic Accuracy for Sepsis in Critically Ill Patients: A Prospective Observational Study. Indian J Crit Care Med 2025; 29 (3):268-272.
Objective: Sepsis stands as a significant contributor to mortality in ICU settings worldwide. Early diagnosis and appropriate treatment are therefore essential to reduce mortality. We planned this study to investigate the diagnostic significance of prokineticin-2 (PK-2) in patients with sepsis.
Materials and methods: Adult patients with sepsis who were admitted to our intensive care unit (ICU) were included in this prospective observational study. On the day of admission and the 7th day of the ICU stay, the levels of procalcitonin (PCT) and PK-2 were assessed. Patients’ mortality was observed for 28 days.
Results: This research involved 83 patients meeting the inclusion criteria. Prokineticin-2 showed a diagnostic sensitivity of 70.6% for sepsis, outperforming PCT with a sensitivity of 64.7%. In predicting mortality, PCT displayed a sensitivity of 95.5%, whereas Prokineticin-2 demonstrated an even higher sensitivity at 98.4%.
Conclusion: Prokinectin-2 can be used for screening adult patients with sepsis admitted to ICU.
Juneja D, Nasa P, Chanchalani G, Cherian A, Jagiasi BG, Javeri Y, et al. The Indian Society of Critical Care Medicine Position Statement on the Management of Sepsis in Resource-limited Settings. Indian J Crit Care Med 2024; 28(Suppl 2): S4–S19. DOI: 10.5005/jp-journals-10071-24682.
Samransamruajkit R, Limprayoon K, Lertbunrian R, Uppala R, Samathakanee C, Jetanachai P, et al. The utilization of the surviving sepsis campaign care bundles in the treatment of pediatric patients with severe sepsis or septic shock in a resource-limited environment: A prospective multicenter trial. Indian J Crit Care Med 2018;22(12):846–851. DOI: 10.4103/ijccm.IJCCM_367_18.
Cohen M, Banerjee D. Biomarkers in sepsis: A current review of new technologies. J Intensive Care Med 2024;39(5):399–405. DOI: 10.1177/08850666231194535.
Zaki HA, Bensliman S, Bashir K, Iftikhar H, Fayed MH, Salem W, et al. Accuracy of procalcitonin for diagnosing sepsis in adult patients admitted to the emergency department: A systematic review and meta-analysis. Syst Rev 2024;13(1):37. DOI: 10.1186/s13643-023-02432-w.
Farooq A, Colon-Franco JM. Procalcitonin and its limitations: Why a biomarker's best isn't good enough. J Appl Lab Med 2019 ;3(4):716–719. DOI: 10.1373/jalm.2017.025916.
Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteremia: A systematic review and meta-analysis. Clin Microbiol Infect 2015 ;21(5):474–481. DOI: 10.1016/j.cmi.2014.12.026.
He RR, Yue GL, Dong ML, Wang JQ, Cheng C. Sepsis biomarkers: advancements and clinical applications-A narrative review. Int J Mol Sci 2024 ;25(16):9010. DOI: 10.3390/ijms25169010.
Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem 2019;120(4):5852–5859. DOI: 10.1002/jcb.27870.
Martin-Loeches I, Singer M, Leone M. Sepsis: Key insights, future directions, and immediate goals. A review and expert opinion. Intensive Care Med 2024;50(12):2043–2049. DOI: 10.1007/s00134-024-07694-z.
Tu Q, Yu X, Xie W, Luo Y, Tang H, Chen K, et al. Prokineticin 2 promotes macrophages-mediated antibacterial host defense against bacterial pneumonia. Int J Infect Dis 2022;125:103–113. DOI: 10.1016/j.ijid.2022.10.003.
Yu X, Chen J, Tang H, Tu Q, Li Y, Yuan X, et al. Identifying Prokineticin2 as a novel immunomodulatory factor in diagnosis and treatment of sepsis. Crit Care Med 2022;50(4):674–684. DOI: 10.1097/CCM.0000000000005335.
Conway Morris A. New movement in sepsis immunotherapeutics-a role for Prokineticin 2? Crit Care Med 2022;50(4):714–716. DOI: 10.1097/CCM.0000000000005375.
